You are here

  • Home
  • Archive
  • Volume 33, Issue 8
  • Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database

Citation Tools

Article menu
Download PDFPDF
Original research
Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
He Z, Mo J, Jiang W, et al
Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database
International Journal of Gynecologic Cancer 2023;33:1237-1246.